Drug Development

Vernalis shares slide after FDA turn thumbs down on their latest XR cold med

Ian Garland, Vernalis

Five years ago Vernalis and Tris Pharma came up with a plan to develop a portfolio of branded cold meds, using Tris’ extended-release tech to tweak existing medications and turn them into an easier-to-use formulation. That worked on the first try, producing an FDA approval for Tuzistra XR — codeine polistirex and chlorpheniramine polistirex — in the fall of 2015. But the partners ran into a hitch today, with the FDA throwing the red flag on their second try.

According to a brief statement out this morning from Vernalis, regulators say that CCP-07 is not ready for prime time in the US. But the company provided little insight on what went wrong, or what needs to be fixed.

Their statement:

The CRL did not raise any concerns with the formulation or pharmacokinetic profile of CCP-07 but did identify outstanding items that need to be addressed prior to the resubmission and approval of the NDA.

Shares of Vernalis {LSE: VER} took a hit on the news, dropping 13%.

The idea here is a relatively modest one. Tris uses its tech and the partners execute a bioavailability study to prove to the FDA that it works like the original, just with less dosing. And they envision a set of up to six of these drugs that can be marketed to primary care groups. The third, CCP-08, is being teed up for an application now.

We have no idea, though, what regulators think about their number 2 drug, because CRLs are kept private.

“We remain committed to the approval of CCP-07 and will work closely with the FDA to resubmit the NDA as quickly as possible” said Ian Garland, CEO of Vernalis.


The best place to read Endpoints News? In your inbox.

Full-text daily reports for those who discover, develop, and market drugs. Join 19,000+ biopharma pros who read Endpoints News by email every day.

Free Subscription

BioNJ CEO Summit 2017